Oncolytics Completes Patient Enrollment in Cancer Trial

Canadian drugmaker Oncolytics Biotech has started its Phase Ia/Ib UK trial investigating the intratumoral delivery of Reolysin in combination with radiation to treat patients with advanced cancers.

The trial’s primary objective is to determine the drug’s maximum tolerated dose, dose-limiting toxicity and safety profile.

Twenty-three patients received two to six intratumoral doses of Reolysin at escalating doses, and the treatment appears to have been well tolerated, according to Oncolytics.